昭衍新药(06127)将向舒泰神集团提供涵盖非临床及临床试验阶段的全方位医药研发服务

智通财经
20 Dec 2024

智通财经APP讯,昭衍新药(06127)发布公告,于2024年12月20日,本公司与舒泰神订立2025年舒泰神研发服务框架协议,期限为2025年1月1日至2025年12月31日。本公司须按2025年舒泰神研发服务框架协议向舒泰神集团提供涵盖非临床及临床试验阶段的全方位医药研发服务。

由于与舒泰神集团的长期合作使我们能够进一步开拓医药合同研究组织服务市场并提高我们的品牌声誉,董事认为2025年舒泰神研发服务框架协议与本公司的业务及商业目标一致。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10